Mechanisms and Therapeutic Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure
Abstract
Heart failure (HF) is a major global cause of hospitalization and mortality, representing a complex clinical syndrome with significant unmet therapeutic needs. Sodium-glucose cotransporter 2 inhibitors (SGLT2is), originally developed for glycemic control, have recently demonstrated remarkable efficacy in the management of HF. This review comprehensively examines the mechanisms of action and therapeutic potential of SGLT2is in HF, with a focus on their multifaceted effects on hemodynamics, cardiac metabolism, inflammatory responses, oxidative stress, and neuroendocrine activation. In addition, clinical trial outcomes and safety profiles of SGLT2is in HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), and HF with mid-range ejection fraction (HFmrEF) are thoroughly evaluated. Finally, this article discusses future research directions and clinical application prospects, aiming to provide novel insights and strategies for treating HF.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.